Randomized trial · people

NAD+ improved LVEF at 1 month in ischemic heart failure

Checked against the paper Randomized trialPublished by PepVault

The takeaway

A short course of IV NAD+ added to standard care gave a modest LVEF gain at 1 month in ischemic heart failure, while effects on hospital stays and symptoms remain unconfirmed.

Kind
Randomized trial
Studied in
People
Number studied
180
Published
2026
Journal
Am J Cardiovasc Drugs

What they tested

The team tested whether NAD+ given into a vein improves heart function and clinical outcomes in people with heart failure caused by ischemic cardiomyopathy, heart muscle damage from poor blood flow.

How the study was done

A single-center, randomized, placebo-controlled trial in 180 adults with ischemic cardiomyopathy, an LVEF (the share of blood the heart pumps out with each beat) of 45% or less, and NYHA class II-III symptoms (mild to marked limits on activity). Patients got either IV NAD+ at 10 mg/day or a placebo drip (5% glucose/normal saline) for 7 days on top of standard heart failure medicines, with follow-up to 6 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking NAD+? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 1 month, LVEF improved more in the NAD+ group than in the placebo group (45.44% vs 42.44%, p = 0.024), the trial's main result. NT-proBNP, a blood marker of heart strain, was lower with NAD+ at day 7 (1471.00 vs 2317.50 pg/mL), but this did not reach statistical significance (p = 0.102). Major heart and brain events over 6 months were 14.6% with NAD+ vs 24.7% with placebo (p = 0.089), mostly from fewer first unplanned heart failure hospital stays (13.5% vs 23.6%, p = 0.078). Better NYHA class was more common with NAD+ at 1 month (73.0% vs 57.3%) and 6 months (53.9% vs 39.3%), but these differences were not statistically significant, and heart size measures did not change differently between groups.

What it doesn’t show

This was a small, single-center trial with only 7 days of treatment, and only the LVEF change reached statistical significance; the gaps in hospital stays, events and symptoms could be chance. It looked only at people with heart failure from ischemic cardiomyopathy getting IV NAD+, not other forms of heart failure or other ways of taking NAD+.

The paper

Yu et al. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs. 2026.

The compound

More studies on NAD+

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking NAD+? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo